Addiction Control Therapeutics - Pipeline Assessment and Market Forecasts to 2017

March 14, 2011 - PRLog -- GlobalData, the industry analysis specialist, has released its new report, “Addiction Control Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Addiction Control market. The report identifies the key trends shaping and driving the global Addiction Controlmarket. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Addiction Control sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Addiction Control Market is Forecast to grow until 2017

GlobalData estimated the addiction control market to be worth $4,206m in 2009 and forecast it to grow at a rate of 4.7% annually for the next eight years to reach $6,052m by 2017. The addiction control market has relatively high growth, as the market has relatively few treatment options, meaning that physicians are not left with many choices, which translates into a high prescription rate for existing branded and generic products. In addition, the successful launch of NicVAX, which is currently in Phase III, may significantly stimulate market growth in the near future. The global addiction control market in 2009 primarily consisted of drug classes such as dopamine and norepinephrine reuptake inhibitors and opoid receptor antagonists. However, the low treatment seeking rate and patent expiry of the current major marketed products such as Suboxone/Subutex, Campral, Nicotine Replacement Therapies (NRTs) and Zyban will act as a barrier to market growth.

Addiction Control Therapeutics, Global, Revenue and Market Forecast ($m), 2001-2017

Source:  Globaldata, Epidemiology-Based Market Forecasting Model, Primary Research Interviews, KOL Interviews

Nicotine Addiction Pipeline Raises Some Hope for the Addiction Control Therapeutics Market Growth

GlobalData found that the pipeline in the nicotine addiction control market is strong, with 14 molecules in various phases of clinical development. There are eight first-in-class molecules over all the phases of clinical development, out of which six molecules are company-sponsored.

These first-in-class molecules have a distinct advantage over the currently marketed products for addiction control in terms of reducing or eliminating addiction to nicotine and preventing relapses.

The nicotine addiction control pipeline has a vaccine NicVAX, from Nabi Biopharmaceuticals, in its late stage which has a novel mechanism of action and is targeted to help people overcome their addiction and stop smoking permanently. This vaccine is expected in the market in 2012 and is hopeful to capture a large market share. However, TA-NIC and NIC-002 for nicotine addiction, currently in Phase II, are some of the promising vaccines being developed to address the unmet need in the nicotine addiction control market. If launched, these products are expected to meet patients’ expectations and will give physicians more choice in treating addiction conditions.

However, the pipeline for drug abuse control and the alcohol addiction control market are weak. The pipeline for drug abuse control and alcohol addiction control has in total 58 molecules. But most of these molecules are me-toos and generics, or are in the early stages of development. Newer therapies therefore need to compete with the already approved products in order to be successful in the addiction control therapeutics market.

The Current Competition in the Addiction Control Market is Strong

GlobalData found that the current competition in the addiction control market is strong. Pfizer, GlaxoSmithKline (GSK), Merck, Alkermes and Eli Lilly and company remain the leading competitors in the global addiction control market. The competitive landscape is sparsely populated by six branded products, which are significantly strong and efficacious in meeting patients’ expectations. While the market remains well served by opioid receptor antagonists and dopamine and norepinephrine reuptake inhibitors, the newer candidates will not have much scope for growth and profitability. The currently used classes of therapy in the addiction control market are effective and the market is dominated by brands which are affordable for patients.

Current Treatment Options Satisfy the Market Demand

GlobalData found that although there is a narrow range of treatments, the current market requirement is met efficiently by the currently available treatment options from different classes of therapy. The nicotine addiction control market is well served by products such as Pfizer’s Chantix(vareniciline), an alpha-2 adrenergic receptor agonist which has generated a huge market share in the past years, and with other products such as GSK’s Zyban(Bupropion) and other NRTs.
The drug abuse market has Merck’s suboxone/subutex which is highly effective in the treatment of opioid dependence. The alcohol addiction market has Alkermes’ opioid receptor antagonist Vivitrol (naltrexone), which is effective in reducing and limiting the patient’s intake of alcohol. As a result, the global addiction control market has treatment options which satisfy the market demand. For more details, please vist http://www.reportreserve.com/reportdet.php?company=Global...

# # #

ReportReserve is an online research report distribution company. The company lists several market research reports published by several research houses across the globe.